Evidence map›Paper›PMID 40653497›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

m5C-modified circRREB1 promotes lung cancer progression by inducing mitophagy.

Dunyu Cai, Xingcai Chen, Haotian Xu, Qingyun Zhao, Xiaodong Zhou, Jiaxi Wu, Shengyi Yuan, Yihong Gao, Deqing Li, Ruirui Zhang and 3 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. mBiology direct · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. RNA 5-Methylcytosine Modification in Myocardial Fibrosis.Reviews in cardiovascular medicine · 2025
    Review
  10. NSUN2-mediated m5C hypermethylation ofNon-coding RNA research · 2025
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dunyu Cai *School of Public Health, Guangxi Medical University, Nanning, 530021, China.
Xingcai Chen *School of Public Health, Guangxi Medical University, Nanning, 530021, China.
Haotian Xu *School of Public Health, Guangxi Medical University, Nanning, 530021, China.
Qingyun ZhaoSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Xiaodong ZhouSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Jiaxi WuSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Shengyi YuanSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Yihong GaoSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Deqing LiSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Ruirui ZhangSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Wenyi PengSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Gang LiSchool of Public Health, Guangxi Medical University, Nanning, 530021, China.
Aruo NanSchool of Public Health, Guangxi Medical University, Nanning, 530021, China. nanaruo@163.com.

Funding

National Natural Science Foundation of China NSFC82260652Natural Science Foundation of Guangxi 2023GXNSFFA026006
6 · The paper itself

Abstract

backgroundLung cancer is the most common malignant tumour and the leading cause of cancer-related death. circular RNAs (circRNAs) have important biological functions and are closely related to tumour development. The 5-methylcytosine (m5C) modification can regulate the molecular fate of RNA molecules and thus influence disease development.

methodsHigh-throughput RNA sequencing was used to construct the differential expression profiles of circRNAs. The m5C modification of circRREB1 was explored through methylated RNA immunoprecipitation (MeRIP) and crosslinking-immunoprecipitation (CLIP). RNA stability experiments, fluorescence in situ hybridization (FISH), and nuclear-cytoplasmic fractionation experiments were performed to explore the effects of the m5C modification on circRREB1. A system for the silencing and overexpression of circRREB1 was established, and in vitro and in vivo experiments were conducted to study the biological functions of circRREB1. Tagged RNA affinity purification (TRAP), RNA immunoprecipitation (RIP), and coimmunoprecipitation (Co-IP) experiments were conducted to reveal the molecular mechanisms of circRREB1.

resultsIn this study, we found that circRREB1 is highly expressed in lung cancer tissues and cells and that patients with high circRREB1 expression have a poor prognosis. We discovered that circRREB1 undergoes the m5C modification mediated by the methyltransferase NSUN2. This modification facilitates its nuclear export via the m5C reader ALYREF. Functional studies demonstrated that circRREB1 promotes lung cancer progression both in vitro and in vivo. Mechanistically, circRREB1 directly binds to HSPA8 and stabilizes it by inhibiting ubiquitin-dependent degradation, thereby inducing mitophagy through the HSPA8/PINK1/Parkin signalling axis and ultimately promoting the development of lung cancer.

conclusionsThis study revealed the presence of m5C modifications on circRREB1 and showed that m5C-modified circRREB1 can induce mitophagy, ultimately promoting lung cancer. These findings provide not only a theoretical basis for further exploration of the mechanisms underlying lung cancer development but also potential targets for lung cancer therapy.

Indexed as

5-MethylcytosineLung NeoplasmsMitophagyRNA, CircularAnimalsCell Line, TumorDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Nude5-MethylcytosineRNA, CircularcircRREB1Lung cancerm5C modificationMitophagy

Identifiers

PMID40653497
PMCPMC12257754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.